PEY5 COMPARISON OF PHYSICIAN AND PATIENT-REPORTED OUTCOMES OF ADULTS WITH DRY EYE DISEASE (KERATOCONJUNCTIVITIS SICCA) MANAGED OVER TIME IN A PATIENT REGISTRY  by Steeds, CS et al.
A367Abstracts
information, brinzolamide is more efﬁcient than brimonidine in
the treatment of glaucoma patients, in mono-therapy, in all treat-
ment lines. Patients remained treated longer with brinzolamide.
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OBJECTIVE: To compare physician and patient rating of dry
eye disease severity over time, with standard clinical tests and a
QoL measure within a patient registry. METHODS: Patients
with moderate to severe dry eye disease, who were attending the
dry eye clinic at the Royal Victoria Inﬁrmary in Newcastle, UK,
and consented to participate in a patient registry, were recruited.
Patients were managed as in routine clinical practise. Patients
and physicians rated disease severity at baseline and over time
on a scale of 0–9 (0 Normal, 1–3 Mild, 4–6 Moderate, 7–9
Severe). In addition, a range of standard clinical tests for dry eye
and a validated, quality of life instrument (Ocular Surface
Disease Index—OSDI®) were completed. RESULTS: Data from
75 patients were analysed, 91% were white females and 84%
were postmenopausal. Fifty-nine percent of patients had at least
4 follow up visits (mean time approx. 16 months). At baseline,
46% of patients rated their dry eye disease as moderate and 43%
as severe, compared to 62% as moderate and 36% as severe by
the physician. From baseline to visit 4, the change in disease
severity by category was 38% improved, 41% same and 21%
deteriorated by the patient’s assessment. In comparison, by the
physician’s assessment, 49% of patients improved, 49% stayed
the same and 2% deteriorated. The patient’s rating of their
disease correlated well with the OSDI® (Spearman correlation
coefﬁcient; 0.53, p < 0.001). The physician’s rating of disease
status correlated well with 2 of the standard clinical tests for dry
eye (Oxford staining; 0.50, p < 0.001 and Tear Function Index;
0.43, p < 0.001). CONCLUSIONS: Patients tend to rate their
dry eye disease as more severe than the physician. It is impor-
tant to include patient-reported outcomes as part of the assess-
ment of dry eye disease severity and the management of patients.
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OBJECTIVE: To compare the rate of capsulotomy with Nd:Yag
laser following cataract surgery involving intra-ocular (IOL)
implantation with three square edge IOL’s (hydrophobic acrylic
single piece IOL: Acrysof SA60AT, Alcon, hydrophobic acrylic
multi-piece IOL: AR40E, AMO, and hydrophilic acrylic single
piece IOL: XL-Stabi, IOLTech) after three years follow-up.
METHODS: A retrospective review of patients with at least one
eye having been implanted with an IOL, aged 50 to 85 years at
the time of surgery, operated on for cataract in 2001 or 2002 in
10 French surgical centers. Centers were recruited if they had
implanted at least 2 of the studied types of IOL’s in order to study
center effect. Medical charts of patients meeting inclusion and
exclusion criteria were reviewed to collect information during
the three year period following cataract surgery to identify
patients who had posterior capsular opaciﬁcation (PCO) requir-
ing Nd:YAG laser post-operatively. Data on the type of IOL
implanted was extracted from the patients’ charts, as was the
date and outcome of the Nd:YAG laser intervention. Kaplan-
Meier survival curve analysis with time to Nd:YAG laser analy-
sis was performed on the data and adjusted in Cox models for
center effect due to possible differences in Nd:YAG practices.
RESULTS: A total of 777 cataract patients were included and
analyzed (n = 256 for SA60AT, n = 256 for AR40E, n = 265 for
XL-Stabi). The 3-year rates of cataract patients with the oper-
ated eye free of PCO requiring Nd:YAG laser treatment were
88.3% with SA60AT, 75% with AR40E and 49.1% with XL-
Stabi (p < 0.0001). Adjusted Cox model gave a risk-ratio (RR)
of 2.88 for AR40E (p < 0.0001) and a RR of 5.217 for XL-Stabi
(p < 0.0001) compared to SA60AT (reference). CONCLUSION:
Cataract patients receiving the Acrysof SA60AT IOL implant 
had the lowest rate of PCO requiring Nd:YAG laser treatment
post-operatively.
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OBJECTIVE: This study estimated the incremental costs of using
olopatadine (Opatanol) compared to branded cromoglycate
(Opticrom) and generic cromoglycate in the treatment of season
allergic conjunctivitis (SAC) in the UK. METHODS: A literature-
based decision model was constructed depicting the management
of SAC sufferers >=4 years of age over four months (a typical
allergy season). The model considers the decision by a GP to ini-
tially treat a patient with olopatadine (1 drop in affected eyes
twice daily), branded and generic cromoglycate (1 or 2 drops in
affected eyes 4 times daily). Whilst published studies demostrate
olopatadine’s greater symptom reduction compared to cromo-
glycate, there was no evidence of any signiﬁcant differences
between the two treatments in terms of days of treatment and
overall probability of being successfully treated. Therefore, for
the purposes of this analysis both drugs were assumed to be
equally effective. Consequently, a cost-minimisation analysis was
performed to identify the least costly alternative from the per-
spective of the UK’s National Health Service (NHS). RESULTS:
Starting treatment with olopatadine is expected to lead to a
health care cost of GBP 92 (95%CI:46–150) over four months
compared to GBP 109 (95% CI:65–166) with branded cromo-
glycate and GBP 95 (95% CI: 51–152)with generic cromogly-
cate. Consequently, use of olopatadine instead of branded or
generic cromoglycate is expected to lead to a 16% and 3%
reduction in health care costs respectively over four months of
treatment. This cost-difference is primarily due to fewer GP visits
among olopatadine-treated patients. CONCLUSIONS: Use of
olopatadine instead of branded or generic cromoglycate affords
an economic beneﬁt to the NHS. Hence, within the limitations
of our model, olopatadine is the preferred ﬁrst-line treatment for
use in SAC sufferers, since it is expected to release health care
resources for alternative use and may offer better symptom
reduction to patients.
